Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 1.84
Ask: 1.96
Change: -0.14 (-6.86%)
Spread: 0.12 (6.522%)
Open: 2.00
High: 2.01
Low: 2.00
Prev. Close: 2.04
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Ground Rents Income Fund's portfolio value drops

Thu, 22nd Dec 2022 21:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Ground Rents Income Fund PLC - London-based investment company focusing on long-dated UK ground rents - Portfolio valuation per share on September 30 is 92.50 pence, down 0.6% from 93.60p on March 31 and down 8.7% from 103.10p a year earlier. Portfolio valuation is GBP109.0 million, down from GBP110.0 million on March 31 and down from GBP119.4 million a year earlier. Says 21% of portfolio value was subject to a material valuation uncertainty clause, with a negative valuation adjustment for building safety regulatory reform of GBP11.4 million. Further progress since September 30 valuation means the relevant percentage of assets impacted is now approximately 17%. The valuation also includes a negative valuation adjustment for residential leasehold regulatory reform of GBP3.8 million. Chair Barry Gilbertson says: "The company continues to operate in an increasingly challenging regulatory environment, and we are working hard to protect both our leaseholders' interests and our shareholders' investments."

----------

ImmuPharma PLC - London-based specialist drug discovery and development company - Says it is engaging with potential commercial partners on all development programmes across its portfolio, including for exclusive US rights for P140 drug, also known as Lupuzor. Will continue these discussions in January. Executive directors Tim McCarthy and Tim Franklin decide to waive GBP187,500 and GBP159,500 in remuneration respectively, or 64% and 63% of their total remuneration respectively. Says this is to ensure failure to advance P140 into its next clinical trial in 2022 does not negatively impact ImmuPharma's share price and valuation. Says it looks forward with optimism to 2023 and that the board has clear objectives of advancing P140 into its next clinical trial. This is alongside intending to deliver positive advances across the whole portfolio in clinical development and commercial partnerships.

----------

Power Metal Resources PLC - London-based exploration company focusing on global metal discoveries - Chief Executive Officer Paul Johnson says Power Metals enters 2023 with "excitement and optimism". Says he believes in the junior resource sector and its potential for consideration returns for investors. Says the sector is driven by cyclicity driven by shifting supply and demand fundamentals for the underlying metals. Johnson says: "After a long-sustained bear market for resource juniors, I believe that the sector recovery has now begun as demonstrated by rising metal prices and the evident growing demand for metals in most industrial settings and for investment security." Announces five acquisitions which "each have he potential to add considerably to the Power Metal balance sheet".

----------

Iconic Labs PLC - London-based media and technology business focusing on online marketing, content and technology-driven products - Enters into GBP3 million financing facility with the European High Growth Opportunities Securitization Fund on September 28. Enters facility via the issue and subscription of loan notes convertible into new shares with share subscription warrants attached. Intends to drawdown on the financing facility in up to 14 sequential tranches over a maximum period of 18 months. Each note has a duration of 24 months from the date of issue. Submits drawdown notice on Thursday to EHGO for the first tranche of GBP250,000. The subsequent tranches will be GBP150,000 each from the second tranche until the sixth tranche, and GBP250,000 each from the seventh tranche until the 14th tranche.

----------

Restaurant Group PLC - London-based operator of around 400 restaurants and pub restaurants across the UK - Amends and extends its debt facilities. This includes a revised GBP340 million package comprising a GBP220 million term loan facility and a GBP120 million revolving credit facility with its existing lenders. Says this represents around a GBP21 million early repayment of its previous facilities. Extends debt facilities for two years, with the maturity on the term loan extending to April 2028 and until March 2027 for the RCF. Says it continues to have a strong liquidity position with over GBP140 million in cash headroom. Says its net leverage covenant for the next financial year is 5.0 times for the June 2023 covenant test, up from a previous position of 4.5x, and 4.75x for the December 2023 covenant test, up from 4.0x.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
2 Apr 2024 12:52

Immupharma jumps amid new IP strategy for P140 technology platform

(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.

Read more
25 Mar 2024 12:20

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 10:55

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
6 Mar 2024 13:05

EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up

(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Dec 2023 17:52

EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Dec 2023 12:18

IN BRIEF: Incanthera signs skincare stocking deal, raises GBP1 million

Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise.

Read more
7 Sep 2023 17:07

TRADING UPDATES: RA International loss narrows as revenue grows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
31 Aug 2023 13:05

ImmuPharma launches GBP2 million fund raise as interim loss narrows

(Alliance News) - ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under GBP2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses.

Read more
21 Aug 2023 12:33

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

(Alliance News) - Incanthera PLC and ImmuPharma PLC on Monday agreed a 12 month extension to their warrant instrument.

Read more
23 Jun 2023 15:51

UK shareholder meetings calendar - next 7 days

Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
Thursday 29 June 
3i Group PLCAGM
Africa Opportunity Fund LtdAGM
Anemoi International LtdAGM
Anpario PLCAGM
Ariana Resources PLCAGM
Beowulf Mining PLCAGM
Celadon Pharmaceuticals PLCAGM
Cornish Metals IncAGM
East Imperial PLCAGM
East Star Resources PLCAGM
Eden Research PLCAGM
Engage XR Holdings PLCAGM
First Class Metals PLCAGM
Gresham House Energy Storage Fund PLCGM re remuneration policy
Gusbourne PLCAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Ingenta PLCAGM
IQE PLCAGM
Kooth PLCAGM
Landore Resources LtdAGM
Let's Explore Group PLCAGM
Likewise Group PLCAGM
MGC Pharmaceuticals LtdGM re issue of convertible notes
Morgan Advanced Materials PLCAGM
NetScientific PLCAGM
New Century AIM VCT 2AGM
Norman Broadbent PLCAGM
Reabold Resources PLCAGM
Rockhopper Exploration PLCAGM
Roquefort Therapeutics PLCAGM
Serica Energy PLCAGM
SpaceandPeople PLCAGM
Symphony Environmental Technologies PLCAGM
Synairgen PLCAGM
Thalassa Holdings LtdAGM
tinyBuild IncAGM
Touchstone Exploration IncAGM
Trident Royalties PLCAGM
Unigel Group PLCAGM
Verici Dx PLCAGM
Xpediator PLCAGM
Friday 30 June 
Argo Blockchain PLCAGM
Ascent Resources PLCAGM
Bluejay Mining PLCAGM
Caspian Sunrise PLCAGM
Codex Acquisitions PLCAGM
Domino's Pizza Group PLCGM re directors' remuneration policy
Fenikso LtdAGM
Fiinu PLCAGM
FireAngel Safety Technology Group PLCAGM
GENinCode PLCAGM
Hemogenyx Pharmaceuticals PLCAGM
Hiro Metaverse Acquisitions I SAAGM
i3 Energy PLCGM re premium share cancellation
ImmuPharma PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kefi Gold & Copper PLCAGM
Kistos Holdings PLCAGM
KRM22 PLCAGM
Kropz PLCAGM
LoopUp Group PLCAGM
Medica Group PLCAGM
Mirriad Advertising PLCAGM
Rockfire Resources PLCAGM
Savannah Energy PLCAGM
Strip Tinning Holdings PLCAGM
ThomasLloyd Energy Impact Trust PLCAGM
URA Holdings PLCAGM
World Chess PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jun 2023 12:02

IN BRIEF: ImmuPharma to start next two phases of Lupuzor trial

ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food & Drug Administration. Says the clinical trial will be supported by Avion Pharmaceuticals. Adds further details of the trial will be shared at a later stage. Lupuzor, or P140, is a potential treatment for Lupus disease.

Read more
18 May 2023 12:12

IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus.

Read more
11 May 2023 11:48

IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market."

Read more
19 Apr 2023 15:40

IN BRIEF: ImmuPharma says US FDA confirms date for Lupuzor meeting

ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.